CDMOs offering Upstream Processing with Biologics (Monoclonal Antibodies)
26 published
26 published CDMOs match Upstream Processing and Biologics (Monoclonal Antibodies).
Locations in this set include United States, China, India, Japan, Germany, and Switzerland.
Capabilities that show up most often in this set: CMC Analytical Development, Downstream Processing, Recombinant Protein Manufacturing, Process Development, and Cell-Line Development.
Matching companies
Rodon BiologicsRodon Biologics is a biotech CRO/CDMO with over 20 years of activity. It offers protein engineering, recombinant protein production, cell line and process development, manufacturing, and analytical and stability testing services for biologics.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi BiologicsGlobal biologic CDMO offering end-to-end solutions from discovery to commercialization.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Yapan BioYapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.
Markdown mirror: /explore/upstream-processing/biologics-monoclonal-antibodies.md